Search

Your search keyword '"Steg, Ph. Gabriel"' showing total 802 results

Search Constraints

Start Over You searched for: Author "Steg, Ph. Gabriel" Remove constraint Author: "Steg, Ph. Gabriel"
802 results on '"Steg, Ph. Gabriel"'

Search Results

1. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking

4. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

7. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

8. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome

9. Reduction in Revascularization with Icosapent Ethyl: Insights from REDUCE-IT REVASC

10. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF

11. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

13. REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States

14. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

15. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

16. Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES

19. Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI

22. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial

25. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

27. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial

28. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

30. Effectiveness of Icosapent Ethyl on First and Total Cardiovascular Events in Patients with Metabolic Syndrome, but without Diabetes: REDUCE-IT MetSyn

31. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

33. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

34. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

36. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial

38. Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials

40. Do patients benefit from omega-3 fatty acids?

41. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests

42. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease

44. Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial.

Catalog

Books, media, physical & digital resources